JP2016534048A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534048A5
JP2016534048A5 JP2016522040A JP2016522040A JP2016534048A5 JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5 JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016522040 A JP2016522040 A JP 2016522040A JP 2016534048 A5 JP2016534048 A5 JP 2016534048A5
Authority
JP
Japan
Prior art keywords
cancer
compound according
aryl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016522040A
Other languages
English (en)
Japanese (ja)
Other versions
JP6765302B2 (ja
JP2016534048A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/050974 external-priority patent/WO2015051458A1/en
Publication of JP2016534048A publication Critical patent/JP2016534048A/ja
Publication of JP2016534048A5 publication Critical patent/JP2016534048A5/ja
Application granted granted Critical
Publication of JP6765302B2 publication Critical patent/JP6765302B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016522040A 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物 Expired - Fee Related JP6765302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887988P 2013-10-08 2013-10-08
US61/887,988 2013-10-08
PCT/CA2014/050974 WO2015051458A1 (en) 2013-10-08 2014-10-08 Non-platimun-based anti-cancer compounds for use in targeted chemotherapy

Publications (3)

Publication Number Publication Date
JP2016534048A JP2016534048A (ja) 2016-11-04
JP2016534048A5 true JP2016534048A5 (enExample) 2018-02-15
JP6765302B2 JP6765302B2 (ja) 2020-10-07

Family

ID=52812401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522040A Expired - Fee Related JP6765302B2 (ja) 2013-10-08 2014-10-08 標的化化学療法に使用するための非白金ベースの抗がん化合物

Country Status (8)

Country Link
US (2) US10463662B2 (enExample)
EP (2) EP3578176A1 (enExample)
JP (1) JP6765302B2 (enExample)
KR (1) KR102307387B1 (enExample)
CN (2) CN114380700A (enExample)
AU (1) AU2014334461B2 (enExample)
CA (1) CA2926571C (enExample)
WO (1) WO2015051458A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
EA039417B1 (ru) 2017-08-07 2022-01-25 Родин Терапеутикс, Инк. Бициклические ингибиторы гистондеацетилазы
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822261A (en) * 1972-10-30 1974-07-02 Dow Chemical Co 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines
EP0743855A1 (en) * 1994-01-03 1996-11-27 Acea Pharmaceuticals, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
DE102004054545A1 (de) * 2004-09-16 2006-04-06 Max-Delbrück-Centrum für Molekulare Medizin Änderung des Beladungszustandes von MHC-Molekülen
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
ATE523506T1 (de) * 2005-02-16 2011-09-15 Schering Corp Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
US7557221B2 (en) * 2007-08-16 2009-07-07 Hoffman-La Roche Inc. Substituted hydantoins
DK200801600A (en) * 2008-11-17 2010-05-18 Engkilde Kaare Method for treatment of inflammatory diseases
WO2011056652A1 (en) * 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
BR112015014855A2 (pt) * 2012-12-20 2017-07-11 Qing Bin Lu compostos radiossensibilizadores para uso em combinação com radiação

Similar Documents

Publication Publication Date Title
JP2016534048A5 (enExample)
JP2019514863A5 (enExample)
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
JP2019529500A5 (enExample)
JP2019535720A5 (enExample)
JP2010539095A5 (enExample)
JP2017509586A5 (enExample)
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
JP2019518766A5 (enExample)
JP2020506951A5 (enExample)
JP2009534408A5 (enExample)
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2008535902A5 (enExample)
JP2015512943A5 (enExample)
JP2016513137A5 (enExample)
JP2016518328A5 (enExample)
JP2017528502A5 (enExample)
JP2014501766A5 (enExample)
TR201809990T4 (en) NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING.
IL292475A (en) Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
JP2016537382A5 (enExample)
JP2016539985A5 (enExample)
JP2015535851A5 (enExample)
JP2020502268A5 (enExample)